TY - JOUR
T1 - Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation
AU - Frenette, Catherine T.
AU - Boktour, Maha
AU - Burroughs, Sherilyn G.
AU - Kaseb, Ahmed
AU - Aloia, Thomas A.
AU - Galati, Joseph
AU - Gaber, Ahmed O.
AU - Monsour, Howard
AU - Ghobrial, Rafik M.
PY - 2013/7
Y1 - 2013/7
N2 - Hepatocellular carcinoma (HCC) is increasing in incidence, resulting in approximately 35% of orthotopic liver transplantation (OLT) performed each year. Sorafenib (SOR) is a multi-kinase inhibitor that is approved for the treatment of unresectable HCC. Concerns have been raised regarding the safety of SOR in patients undergoing major surgery. We retrospectively reviewed 79 consecutive patients with HCC receiving OLT. Patient data were compared for those who received SOR pre-OLT with those who did not. SOR was continued until time of transplant. During this time period, 15 patients received SOR pre-OLT and 64 did not. The two groups were similar with regards to demographic and clinical data. SOR patients were more likely to have larger tumors, more tumor nodules, and be outside of Milan criteria. The rate of recurrence of HCC was not different between the groups (13% in SOR group, 11% in no-SOR group). Surgical complications were not increased in patients receiving SOR prior to OLT. Survival rate was also similar between the two groups (median follow-up 19.7 months). In this small cohort of patients, use of SOR prior to liver transplantation does not confer an increased risk of surgical complications, even when continued until the day of surgery.
AB - Hepatocellular carcinoma (HCC) is increasing in incidence, resulting in approximately 35% of orthotopic liver transplantation (OLT) performed each year. Sorafenib (SOR) is a multi-kinase inhibitor that is approved for the treatment of unresectable HCC. Concerns have been raised regarding the safety of SOR in patients undergoing major surgery. We retrospectively reviewed 79 consecutive patients with HCC receiving OLT. Patient data were compared for those who received SOR pre-OLT with those who did not. SOR was continued until time of transplant. During this time period, 15 patients received SOR pre-OLT and 64 did not. The two groups were similar with regards to demographic and clinical data. SOR patients were more likely to have larger tumors, more tumor nodules, and be outside of Milan criteria. The rate of recurrence of HCC was not different between the groups (13% in SOR group, 11% in no-SOR group). Surgical complications were not increased in patients receiving SOR prior to OLT. Survival rate was also similar between the two groups (median follow-up 19.7 months). In this small cohort of patients, use of SOR prior to liver transplantation does not confer an increased risk of surgical complications, even when continued until the day of surgery.
KW - hepatocellular carcinoma
KW - liver cancer
KW - orthotopic liver transplantation
KW - sorafenib
KW - surgical complications
UR - http://www.scopus.com/inward/record.url?scp=84879006659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879006659&partnerID=8YFLogxK
U2 - 10.1111/tri.12117
DO - 10.1111/tri.12117
M3 - Article
C2 - 23701126
AN - SCOPUS:84879006659
SN - 0934-0874
VL - 26
SP - 734
EP - 739
JO - Transplant International
JF - Transplant International
IS - 7
ER -